Our website uses cookies

Essential and functional cookies are necessary for the website to function properly and cannot be refused. Other cookies are used for statistical purposes (analysis cookies) and will only be placed if you agree to their placement. See our cookie policy to find out more.

Accept cookies Accept essential cookies only

Disclaimer

You are leaving serb.eu global website.

This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. Serb declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, Serb is not responsible for any information or opinion contained in any third-party website.

OK Cancel

We focus on
critical care

SERB has consolidated a global leading position in Critical Care with Emergency Care (wide range of lifesaving medical countermeasures and intensive care medicines) and Surgery portfolio (drugs and medical devices for supportive care as well as diagnostic agents).

More Info

We focus on
rare diseases

SERB has extended its Rare Diseases portfolio in both Neurology (with treatments for severe epileptic and neuromuscular conditions) and Metabolic Disorders.

More Info

We focus on
global presence

SERB is a global pharmaceutical group with a direct presence in Europe, the Middle East and Australia, plus over 80 countries including USA and Japan through a broad network of experienced distributors.

MORE INFO

Welcome to SERB
Specialty
Pharmaceuticals

SERB is a global specialty pharmaceutical group focused on prescription medicines which address rare and life-threatening diseases.

Following strategic acquisitions and targeted developments, SERB has succeeded in establishing a consistent drugs portfolio focused on niche specialty pharmaceuticals to ensure continuous availability of life-saving medicines and answer unmet medical needs.

Our commitment is to continue to offer essential drugs meeting Public Health needs.

All products

Featured Updates & Articles

SERB receives positive CHMP opinion for Voraxaze® (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity

Read More
SERB completes acquisition of BTG Specialty Pharmaceuticals to create a global leader in critical care medicines

SERB Specialty Pharmaceuticals (“SERB”), a leading European specialty pharmaceutical group focused on prescription medicines that address rare and life-threatening diseases, today announced the acquisition of BTG Specialty Pharmaceuticals, a division of Boston Scientific that develops, manufactures, and commercializes antidotes and rescue medicines to treat patients with critical conditions.

Read More
Ben Watt Joins SERB and BTG as Group CFO

Read More